P
ancreatic cancer ranks as the eighth most frequent type of solid tumor arising worldwide and represents the fourth most frequent cause of death. 1 Although early tumor diagnosis, improved surgical treatment, and multimodal therapeutic concepts have helped to reduce the mortality of patients with pancreatic cancer, the prognosis is still extremely poor; the overall 5 -year survival rate is only 1 -4% after the diagnosis. 2 A chance of cure exists only for a minority of patients with locally limited and surgically resectable tumor. 3 However, of patients who are radically treated by surgical curative resection, 70 -80% will suffer from an incurable local relapse, distant metastases, and peritoneal carcinosis. 4 Although a local relapse might be caused by incomplete resection, distant metastases and peritoneal carcinosis depend on dissemination of malignant cells. 5 Their elimination is the aim of various adjuvant therapy concepts that are currently under investigation, including chemotherapy, 6 immunotherapy, 7 and gene therapy. 8 Hepatocyte growth factor (HGF ), originally identified and cloned as a potent mitogen for hepatocytes, 9 ,10 plays both a biological and a physiological role in development and in tissue regeneration. 11 -13 In malignant tumors, HGF plays a role as a stroma -derived mediator in tumor -stromal interactions that confer invasive, angiogenic, and metastatic potentials through c -Met receptor tyrosine kinase. 14, 15 The c -Met receptor is frequently overexpressed in pancreatic cancer, and HGF stimulates motility and growth of pancreatic cancer cells. 16, 17 HGF in ascitic fluid also strongly stimulates invasion of pancreatic cancer cells, which suggests that HGF may be involved in the aggressive invasion, dissemination, and /or metastasis of postoperative pancreatic cancer. 17 NK4 is composed of the N -terminal hairpin and subsequent four-kringle domains of HGF, and acts as a competitive HGF antagonist dose -dependently. 18 -20 In addition, NK4 is a potent angiogenesis inhibitor, through mechanisms distinct from HGF antagonism. 21 NK4 dose -dependently inhibits pancreatic cancer cell migration and invasion in vitro, 17 and suppresses growth, invasion, and metastasis of human pancreatic carcinoma implanted into the pancreas of nude mice. 22 This study was initiated to examine the efficacy of NK4 to suppress the peritoneal metastases after the curative resection of pancreatic cancer, which occurred frequently and led to poor prognosis. To obtain the NK4, in vivo transfection of NK4 gene was performed using a recombinant adenovirus ( rAd ) vector. We speculated that intraperitoneal injections of adenovirus NK4 (Ad -NK4 ) carrying the NK4 gene would induce NK4 in the abdominal cavity and prevent disseminated tumor cells from developing the metastatic phenotype. We investigated, herein, the antitumor effect of intraperitoneal injections of Ad -NK4 in a nude mouse dissemination model of human pancreatic cancer.
Materials and methods

Construction of rAd
rAd expressing human NK4 was constructed as previously described. 23 Briefly, we used a replication -deficient early region 1 -deleted adenovirus type 5 vector pJM17 24 as a backbone, and corresponding genes were regulated under the cytomegalovirus IE promoter (bp À 299 to 72 ) and simian virus 40 polyadenylation signals. Recombinant Ad -NK4 was produced in cotransfecting 293 cells (human embryonic kidney cells ) with pSV2 + 25 harboring NK4 cDNA 19 and pJM17 by the calcium phosphate method. After recombination, well -isolated plaques were selected from 293 cell monolayers and screened by Southern blot hybridization or reverse transcription polymerase chain reaction. A control vector, which expresses the bacterial b-galactosidase (b -gal; LacZ ), was constructed by the same procedure using pCA17 bearing LacZ gene and pJM17. Recombinant Ad -NK4 and adenovirus LacZ ( Ad -LacZ ) were propagated in 293 cells. Adenovirus titer in plaque -forming units (pfu ) was determined by plaque formation assays following infection of 293 cells in both Ad -NK4 and Ad -LacZ. The multiplicity of infection ( MOI ) was defined as the ratio of the total number of pfu used in a particular infection to the total number of cells to be infected.
Cells and culture conditions
The human pancreatic cancer cell line, AsPC -1, was generously donated by Dr H Iguchi (National Kyushu Cancer Center, Fukuoka, Japan ). AsPC -1 was cultured in RPMI supplemented with streptomycin, penicillin, and 10% fetal bovine serum (FBS ) at 378C in a humidified atmosphere containing 5% CO 2 .
NK4 expression and cell proliferation of Ad -LacZ or Ad -NK4 transduced AsPC -1 cells in vitro A total of 1Â10 5 AsPC -1 cells /well were plated into sixwell tissue culture dishes and infected with Ad -LacZ or Ad -NK4 for 1 hour at 10, 50, and 100 MOI. Then, the culture supernatant was replaced with fresh medium, and the medium was changed every 24 hours. The conditioned media were collected on posttransduction days 1, 4, 8, and 11, and NK4 concentration in the media was measured by enzyme -linked immunosorbent assay (ELISA ) with a human HGF ELISA kit, IMMUNIS HGF EIA (Institute of Immunology, Tokyo, Japan ), according to the manufacturer's recommendations. At the same time, the cell numbers in each well were counted by a particle distribution counter, CDA500 ( Sysmex, Kobe, Japan ). NK4 expression per 1Â10 5 cells was calculated on each day.
Measurement of in vitro migration of AsPC -1 after the infection of Ad -LacZ or Ad -NK4
In vitro migration of the parental and adenovirus -infected AsPC -1 cells was measured with the use of Costar Transwell cell culture chamber inserts ( Corning Inc., Corning, NY ). AsPC -1 cells were infected by Ad -LacZ or Ad -NK4 at 100 MOI for 1 hour, and the medium was changed. After 3 days, the cells were suspended in RPMI containing 10% FBS and added to the inner cup of the chamber at a density of 5Â10 4 cells /cm 2 . HGF (110 pM ) was added to the medium of the outer cup. After a 24-hour cultivation, cells that migrated through the filter membrane with 8-m pores were counted after staining with hematoxylin and eosin (H&E ). Ten microscopic fields ( Â200 ) were randomly selected for cell counting.
Animals and peritoneal transplantation of AsPC -1
Six -week -old female athymic nude mice (BALBc nu/nu) were purchased from Japan SLC ( Hamamatsu, Japan ). The mice were housed in laminar flow cabinets under specific pathogen -free conditions in facilities approved by Kyushu University. AsPC -1 cells were grown to subconfluent, and cell suspensions of 1Â10 6 cells/0.2 mL were transplanted to the peritoneal cavity of nude mice.
Treatment by the repeated intraperitoneal injections of Ad -LacZ or Ad -NK4
The mice receiving peritoneal implantation of AsPC -1 were divided in two groups according to the treatment: Ad -LacZ and Ad -NK4. Ad -LacZ or Ad -NK4 was injected into the peritoneal cavity of the mice, 5Â10 8 pfu / mL, once a week from day 3 after the implantation of AsPC -1. Ten mice (five per group ) were killed on day 40 after the transplantation of AsPC -1, and the number and weight of the disseminated implants in the peritoneal cavity were recorded. In another experiment, 20 mice (10 per group ) were subjected to the survival analysis. Weekly intraperitoneal administration of Ad -LacZ or Ad -NK4 was continued 10 times from day 3 until day 66 after the implantation.
Assessment of transgene distribution by evaluation of the b -gal expression
The tissue samples obtained on day 40 were embedded in OCT compound ( Sakura, Tokyo, Japan ) and snap -frozen on dry ice. Frozen cryostat sections (10 m ) were rinsed twice in phosphate -buffered saline (PBS ) and fixed with 0.25% glutaraldehyde in PBS for 5 minutes at room temperature. b -Gal activity was detected by immersing the section into 5 -bromo -4 -chloro -3 -indolyl -b -galactopyranoside (X -gal ) staining solution (5 mM K 4 FeCN, 5 mM K 3 FeCN, 2 mM MgCl 2 , containing 1 mg /mL X -gal ) for 16 hours at 378C. Sections were lightly counterstained with hematoxylin and mounted.
NK4 expression in the various tissues
When the mice were sacrificed on day 40, tissue samples from the various organs such as the brain, heart, lung, liver, pancreas, spleen, kidney, intestine, peritoneum, and disseminated nodules were obtained to examine the NK4 expression. These samples were homogenized in ice -cold lysis buffer consisting of Triton X -100, 1 M Tris -HCl, 0.5 M EDTA, 1 M NaCl, sodium pyrophosphate, sodium fluoride, sodium orthovanadate, bovine albumin, and dH 2 O. The supernatants were collected by centrifugation. Expression of NK4 was checked by ELISA analysis as described above for the in vitro assay.
Immunohistochemical studies
The disseminated nodules, (more than 2 mm in diameter ), in both groups were subjected to immunohistochemical staining on day 40. Tissue sections (5 m thick ) of formalinfixed, paraffin-embedded specimens were deparaffinized in xylene, and rehydrated in graded alcohol. Sections analyzed for CD31 were microwaved in 1 mM EDTA, pH 8.0, for 10 minutes, and endogenous peroxidase was blocked by use of 3% hydrogen peroxide in PBS for 20 minutes. The samples were washed three times with PBS, incubated for 20 minutes with a protein -blocking solution consisting of PBS containing 1.5% normal goat serum (DAKO, Glostrup, Denmark ), and incubated with the appropriate dilution ( 1:50 ) of mouse monoclonal CD31 antibody, JC /70A ( NeoMarkers, Fremont, CA ) for 1 hour. Next, the samples were incubated with the appropriate dilution ( 1:100 ) of biotinylated anti -mouse IgG ( Vector, Burlingame, CA ) for 30 minutes, followed by peroxidase -conjugated avidinbiotin complex for 30 minutes, with a Vectastain Elite ABC kit ( Vector ). Positive reaction was visualized by incubating the slides with stable 3,3 0 -diaminobenzidine tetrahydrochloride (DOjinDO, Kumamoto, Japan ) for 40 seconds. The sections were rinsed with distilled water, and counterstained with hematoxylin for 15 seconds. Microvessel density ( MVD ) was assessed in tumor areas showing the high density of staining. The vessel numbers were counted in 10 fields per section, with one field magnified 200 -fold ( 0.739 mm 2 /field), and the average counts were recorded. Proliferating cells were detected with antibody against proliferating cell nuclear antigen ( PCNA ) PC10 (DAKO ), and positive reaction was visualized in the same way as in CD31 staining. To quantify PCNA expression, we counted the number of positive cells in 10 random fields per section at Â200. The apoptotic tumor cells within the tumor nodules were revealed with a TUNEL detection kit ( Takara, Shiga, Japan ) according to the manufacturer's recommendations. The number of positive cells was counted in 10 random fields per section at Â200.
Toxicity of NK4 in nude mice
The histological sections were made from the heart, lung, liver, pancreas, spleen, kidney, and intestine obtained on day 40, stained by H&E, and examined for the presence of any evidence of pathological changes in both groups. The blood samples were subjected to the biochemistry tests.
Statistical analysis
Statistical significance was evaluated with Mann -Whitney U nonparametric test. P <.05 based on a two-tailed test was considered to indicate statistical significance. Survival was analyzed by log rank analysis of Kaplan -Meier curves.
Results
NK4 expression and cell proliferation of Ad -NK4 transduced cells in vitro
AsPC -1 cells were infected with Ad -LacZ or Ad -NK4 at 10, 50, and 100 MOI, and the supernatant of culture media was collected on posttransduction days 1, 4, 8, and 11. NK4 expression in Ad -NK4 transduced cells reached peak on day 4 after the transfection and gradually decreased ( Fig 1) . The expression of NK4 increased according to MOI dosedependently. NK4 expression was not detected in Ad -LacZ transduced cells. The proliferation rate of Ad -NK4 transduced cells was not different from that of the Ad -LacZ transduced cells at any of 10, 50, and 100 MOI (data not shown ). This means that autocrine NK4 had no effect on proliferation of Ad -NK4 transduced cells in vitro.
Inhibition of an HGF -induced AsPC -1 migration by autocrine NK4 in the Ad -NK4 transduced cells
As reported previously, 17 the expression of c -Met receptor in AsPC -1 was relatively strong compared to other pancreatic cancer cell lines, and HGF stimulated the migration and invasion of AsPC -1 cells, although the proliferation of AsPC -1 was not stimulated by HGF. To assess the biological activity of autocrine NK4, which was expressed by the Ad -NK4 transduced AsPC -1, the migration potential of the cells was evaluated with Transwell chambers. By the Ad -NK4 infection at 100 MOI, the migration potential of AsPC -1 was approximately reduced to half by autocrine NK4 (Fig 2 ) . In the presence of 110 pM HGF, the number of the migrated AsPC -1 cells was 4-to 5 -fold larger than that in the absence of HGF, and the Ad -NK4 transduced cells completely inhibited the HGF -induced migration by autocrine NK4. This result indicated that autocrine NK4 by Ad -NK4 transduced cells has an efficient activity as an HGF antagonist.
Suppression of peritoneal dissemination by weekly intraperitoneal injections of Ad-NK4
AsPC -1 cells showed aggressive and malignant phenotype in vivo so that intraperitoneally implanted cells never failed to develop the disseminated nodules with no treatment. Macroscopic appearance of peritoneal dissemination after the treatment of Ad -NK4 and Ad -lacZ was shown in Figure 3A . Multiple nodules were noted in the whole abdominal cavity and mostly larger than 5 mm in diameter in the Ad -LacZ group. In contrast, peritoneal dissemination was extremely suppressed in the Ad -NK4 group, being extremely small in number and less in diameter. There was no ascites in both groups. The number and total weight of the disseminated foci were 76.0 ± 11.5 and 999.2 ± 503.1 mg in the Ad -LacZ group, and 4.6 ± 4.2 and 342.6 ± 341.0 mg in the Ad -NK4 group, respectively. The difference was statistically significant (P < .001, .026) (Fig 3B ) .
b -Gal expression in the intraperitoneal tissues of nude mice
On day 40 after the implantation, b -gal expression in the intraperitoneal tissues was examined. Weekly peritoneal injections of Ad -LacZ or Ad -NK4 were five times and the last one was performed on day 38. X -gal staining of the cryostat sections in the Ad -LacZ -treated mice showed the characteristic blue staining in a small number of cells in the disseminated nodules, liver, pancreas, spleen, and mesenterium, and all of the positive cells were in the superficial layers of these tissues (Fig 4) . Hepatocytes in the periportal regions were not stained. No staining was observed in the organs in the Ad -NK4 -treated mice.
NK4 expression in the intraperitoneal tissues of nude mice
Consistent with the distribution of Ad -LacZ, NK4 expression was detected by ELISA in the disseminated nodules, liver, pancreas, spleen, and mesenterium in the Ad -NK4 -treated mice on day 40 after the implantation. The highest expression of NK4 was attained in the liver, followed by pancreas, spleen, mesenterium, and disseminated nodules ( Fig 5 ) . The concentration of NK4 in the disseminated nodules was 4.8± 2.0 ng /g protein. NK4 concentration in the serum was not detected by ELISA. Any tissues in the AdLacZ -treated mice revealed no NK4 expression. On day 100 after the implantation, there was no detectable NK4 expression in any tissues of the five surviving Ad -NK4-treated mice.
Immunohistochemical examination in the disseminated tumors
Histologically, the disseminated tumors showed moderately to poorly differentiated adenocarcinoma and were very similar in both groups. To examine how the growth of disseminated nodules was suppressed in the Ad -NK4 -treated mice, proliferation index, apoptotic index, and MVD in the disseminated tumors were quantified by immunohistochemistry. PCNA staining did not differ between the groups (Fig 6 ) . Apoptotic index determined by TUNEL indicated a higher incidence of apoptosis in the Ad -NK4 group (4.5 ± 1.4% ) than in the Ad -LacZ group (2.4± 1.2%; P < .001 ). MVD was significantly lower ( P <.001) in the Ad -NK4 group ( 10.3± 1.7 vessels per field) than in the AdLacZ group (26.8 ± 3.0 ).
Toxicity by the Ad -NK4 treatment
H&E -stained sections of the various organs of Ad -NK4 -treated mice as well as Ad -LacZ -treated mice revealed no pathological abnormalities. The blood biochemistry tests showed no significant differences in liver and kidney functions between both groups.
Survival
Severe cancer cachexia appeared in Ad -LacZ -treated mice about 4 weeks after the implantation. Ad -LacZ -treated mice were moribund one after another from day 35, and the last mouse died on day 67 (Fig 7) . In contrast, cancer cachexia in Ad -NK4 -treated mice was slight. However, five mice treated by Ad -NK4 died from dissemination-related hydronephrosis, jaundice, or ileus in relatively early time, although the total number of the disseminated foci was not amount. Five of 10 mice survived for more than 70 days, and these mice had only a few disseminated nodules when sacrificed on day 100. The median survival times of the Ad -LacZ and Ad -NK4 groups were 40.0 ± 3.6 and 68.0 ± 28.5 days, respectively. The survival rate of the Ad -NK4 group was significantly higher than that of the Ad -LacZ group ( P= .0041 ).
Discussion
We have demonstrated here that the intraperitoneal injections of Ad -NK4 significantly suppressed the tumor progression of the pancreatic cancer cells disseminated in the peritoneal cavity of nude mice and prolonged their survival. A clinical setting of this experiment was postoperative peritoneal dissemination of pancreatic cancer without other clinical or radiological evidence of the disease. It was reported that minimal residual disease was detected in 29% of the peritoneal cavity in the patients who underwent curative resection of pancreatic cancer, and the occurrence of isolated tumor cells correlated with a poor prognosis. 5 The higher prognostic value of intraperitoneal tumor cells is not fully understood, but the local factors (e.g., secreted growth factors ) may play an important role in the progress of these cells. To evaluate the antitumor effect of NK4 in such a dissemination process, we performed in vivo transfection of NK4 gene by intraperitoneal injection of Ad -NK4 in a nude mouse dissemination model. We set up the early treatment, beginning on day 3 after peritoneal seeding of cancer cells, supposing this as an adjuvant therapy after the surgery. NK4 expression was attained in the disseminated nodules and the intraperitoneal tissues such as liver, pancreas, spleen, and mesenterium. Disseminated nodules were significantly reduced by Ad -NK4 treatment, and the tumors showed decreased number of tumor vessels and increased tumor cell apoptotic index.
Peritoneal dissemination is established by attachment of cancer cells to mesothelial cells and invasion of the cells to the tissues beneath the peritoneum. It was reported that HGF, produced by peritoneal fibroblasts and mesothelial cells, affects the morphology of mesothelial cells in monolayers, and facilitates the disseminated tumor cells' invasion into the peritoneum. 26 Moreover, the HGF -c -Met receptor system is involved in the malignant behavior of various cancer cells. 14, 27, 28 In pancreatic cancer, the c -Met receptor is overexpressed frequently, 16,17,29 -31 and HGF stimulates growth, locomotion, and invasion of various pancreatic cancer cell lines in vitro. 17, 31 In orthotopic model of pancreatic cancer, HGF was supposed to play a major role in acquisition of the invasive phenotype of pancreatic cancers because c -Met expressing pancreatic cancer cells but not c -Met -negative cells was successfully transplanted to the pancreas of nude mice. 22 In our model, Ad -NK4 treatment significantly suppressed the progress of peritoneally inoculated AsPC -1 cells, which overexpressed c-Met receptor, and migration and invasion of which were enhanced by HGF. We postulate that HGF may play a part in the establishment and progression of the disseminated tumor cells, although we cannot deny the relation of various factors, such as other growth factors including transforming growth factor-b and basic fibroblast growth factor (bFGF ).
In addition, angiogenesis is indispensable for tumor growth, and it has been reported that any foci larger than 2 mm require new tumor vessels for their growth. 32 The angiogenic properties of pancreatic cancer remain unclear, partially because pancreatic cancers have been considered hypovascular, based on roentgenographic findings. However, it has been shown that tumor angiogenesis is implicated in the rapid growth and metastasis of pancreatic cancer, 33 and some angiogenesis inhibitors efficiently inhibited tumor growth and metastasis of pancreatic cancer in experimental models. 34 -36 It was recently reported that NK4 is an angiogenesis inhibitor, which not only antagonizes HGFinduced angiogenesis but also abrogates the angiogenesis induced by other angiogenic inducers such as bFGF and vascular endothelial growth factor, and its antiangiogenic activity is likely to be exhibited through mechanisms distinct from its HGF -antagonist activity. 21, 37 In the present study, new tumor vessels in the disseminated nodules were significantly decreased by the Ad -NK4 treatment, and the tumor growth was suppressed with increased apoptotic cells. We supposed that NK4 prevented the progression of disseminated tumor cells as an angiogenesis inhibitor in addition to an HGF antagonist, and the Figure 7 Survival curves in the Ad -LacZ -and Ad -NK4 -treated mice ( n = 10 / group ). Ad -LacZ or Ad -NK4 was injected intraperitoneally once a week from day 3 after the implantation of AsPC -1 cells ( total injection was 10 ). There was a significant difference in the survival times of the mice between the two groups ( P < .01, by log rank analysis of Kaplan -Meier curves ).
improvement of survival in the Ad -NK4 -treated mice implicated that NK4 also inhibited the further extension of peritoneal dissemination.
We also examined here whether the intraperitoneal injection of Ad -NK4 can be a useful approach for the transduction of NK4 gene to the abdominal cavity. The effects of NK4 as an HGF antagonist and an angiogenesis inhibitor depend on continuous local delivery of NK4 in vivo. 21, 22 Adenoviral vectors are commonly used in gene therapy trials because of their efficacy in gene transduction. 38 However, despite its high efficiency of gene transfer, expression of the foreign gene is transient because integration into the host cell genome is rare. We performed the weekly intraperitoneal administrations of Ad -NK4 because NK4 expression reached the maximum on day 4 after the transfection and gradually declined after that in Ad -NK4 transduced AsPC -1 cells in vitro. The repeated intraperitoneal administrations of Ad -NK4 were effective to attain the continuous supply of NK4, and the sixth intraperitoneal injection of Ad -NK4 also accomplished the NK4 expression in the liver, pancreas, spleen, and mesenterium, in addition to the disseminated nodules on day 2 after the injection (on day 40 after the tumor cell implantation). Although NK4 expression in the disseminated tumors was relatively low, additive effects of NK4 secreted from the transfected tissues into the abdominal cavity might also play an important role in suppressing peritoneal dissemination.
Considering that X -gal -stained cells were present only in the superficial layers of the Ad -LacZ transfected organs, the adenovirus vector probably entered the organs through their surfaces after the intraperitoneal injection. The in vivo transfection seemed to be widely achieved in the visceral peritoneum, especially in the regions where a high dose of adenovirus contacted. Previous reports suggested that systemic absorption of adenovirus from the peritoneal cavity was sometimes observed after intraperitoneal injection of adenovirus. 39 Although the gene transfection by the route of blood circulation through lymphatic vessels might be possible, we have not found such a proof in our study. Neither hepatocytes in the periportal regions nor nonabdominal tissues such as brain, lung, and heart were stained by X -gal after the Ad -LacZ intraperitoneal administration. Likewise, NK4 expression was obtained only in the abdominal organs but not in the serum. This local transfection would be suitable to prevent possible adverse effects of NK4.
In summary, we demonstrated that the transduction of adenovirus -mediated NK4 gene to the peritoneal cavity could be achieved by intraperitoneal viral injections, and sustained NK4 expression significantly suppressed the progression of disseminated pancreatic cancer cells and improved survival of Ad -NK4 -treated mice in the xenograft murine dissemination model. We supposed that the therapeutic effects of NK4 were produced by bifunctional activities of NK4 ( HGF antagonist /angiogenesis inhibitor ). Although it is difficult to compare a mouse model with the human clinical situation, this NK4 gene therapy might provide a palliative benefit in the patients with residual peritoneal tumor cells after surgery and may be more useful in combination with standard chemotherapy and radiation, which have been shown to alter local and hepatic recurrence patterns of pancreatic cancer.
